James R. Sulat has been a director since June 2008 and has served as chairman of the board since December 2008. From October 2009 to June 2013, Mr. Sulat served as the Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., a biopharmaceutical company. Mr. Sulat is on the board of directors of Valneva SE, diaDexus, Inc., AMAG Pharmaceuticals, Inc. and Arch Therapeutics, Inc. During the last five years, Mr. Sulat served as a director of Maxygen, Inc. Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University. Mr. Sulat’s qualifications to sit on the board include his experience with public and financial accounting matters, his experience as chief executive officer and chief financial officer at companies within the biopharmaceutical industry and his experience serving on other boards of directors in the biopharmaceutical industry.
Bruce Downey has been a director since June 2009. Mr. Downey has served as a Partner at NewSpring Capital, a venture capital firm, since April 2009. Previously, Mr. Downey was Chairman and Chief Executive Officer of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company that operated in more than 30 countries worldwide and was acquired by Teva Pharmaceuticals in 2008. Mr. Downey is a member of the board of directors of Cardinal Health, Inc. as well as privately held companies. Mr. Downey graduated with honors from Miami University in 1969 and received his law degree, cum laude, from Ohio State. Mr. Downey’s qualifications to sit on the board include his significant experience serving as a chief executive officer of a global generic pharmaceutical company that also had a substantial brand business and an active biologics research and development program, his years serving as a lawyer in private practice and his experience serving on other boards of directors in the biopharmaceutical industry.
Corey N. Fishman has been a director since September 2016. Mr. Fishman currently serves as Chief Executive Officer and Director of Iterum Therapeutics Limited. He previously served as Chief Financial and Chief Operating Officer of Durata Therapeutics, Inc. where he managed a successful IPO and secondary offering, and led the negotiation and sale of the Company to Actavis plc. Prior to Durata, Mr. Fishman served as Chief Financial Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus Company, and served in several leadership roles, including Chief Financial Officer, at MedPointe Healthcare, Inc. Mr. Fishman holds a BA in Economics from the University of Illinois at Urbana-Champaign and an MSM in Finance from the Krannert School of Management at Purdue University. Mr. Fishman’s qualifications to sit on the board include his experience with public and financial accounting matters, and his experience as chief executive officer and chief financial officer at companies within the biopharmaceutical industry.
Dr. Georges Gemayel has been a director since January 2016. Since 2010, he has been a consultant for several biotechnology companies and venture capital funds. From 2008 to 2009, Dr. Gemayel was President and Chief Executive Officer of Altus Pharmaceuticals, Inc. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the Company’s worldwide therapeutics businesses. Dr. Gemayel is also a member of the boards of directors of Raptor Pharmaceutical Corp., Supernus Pharmaceuticals, Inc. and Dimension Therapeutics, Inc. as well as the Chairman of the boards of directors at several privately-held companies. Dr. Gemayel completed his Doctorate in Pharmacy at St. Joseph University in Beirut, Lebanon, and earned a Ph.D. in Pharmacology at Paris-Sud University in Paris, France. Dr. Gemayel’s qualifications to sit on the board include his significant management and executive experience in the global pharmaceutical industry.
Dr. Gilman has been a director since June 2016. Dr. Gilman currently serves as the Chairman and CEO of ContraFect Corporation. Prior to that, he served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Before joining Cubist in 2008, Dr. Gilman served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation franchise. Prior to Millennium, he was Group Director at Pfizer Central Research. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple University School of Medicine, and Connecticut College. Dr. Gilman currently serves on the board of directors of publicly traded companies Keryx Biopharmaceuticals, Inc., SCYNEXIS Inc., and Vericel Corporation. He also serves as a member of the board of directors of the Northeastern University Drug Discovery Advisory Board, the Massachusetts Biotechnology Association and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.
Jose Carlos Gutierrez-Ramos, Ph.D. has served as a director since March 2016. Since May 2015, he has served as Chief Executive Officer and President of Synlogic, Inc., a pharmaceutical company. Prior to joining Synlogic, Dr. Gutierrez-Ramos was Group Senior Vice President of Worldwide Research and Development and Global Head of Biotherapeutics Research and Development at Pfizer Inc., a pharmaceutical company, from November 2009 to May 2015. Dr. Gutierrez-Ramos received a B.S. in chemistry from Universidad Complutense de Madrid and his Ph.D. in Immunology from the Universidad Autonoma de Madrid. Dr. Gutierrez-Ramos’ qualifications to sit on the board include his senior executive experience in the pharmaceutical industry, including his significant experience in research and development.
Thomas P. Koestler, Ph.D. has been a director since January 2011. Since March 2010, Dr. Koestler has served as Executive‑in‑Residence at Vatera Healthcare Partners, a private equity company. Prior to joining Vatera Healthcare Partners, Dr. Koestler was Executive Vice President of Schering‑Plough Corporation, a pharmaceutical company, and President of Schering‑Plough Research Institute, the pharmaceutical research and development arm of Schering‑Plough Corporation, which he joined in 2003. Dr. Koestler has also held senior positions at Pharmacia Corporation, Novartis AG, Ortho‑McNeil and Bristol‑Myers Squibb. Dr. Koestler is also a member of the board of directors of Novo Nordisk A/S and a number of privately‑held companies. Dr. Koestler holds a BS degree in biology and genetics from Daemen College and a Ph.D. from the State University of New York, where he studied medicine and pathology. Dr. Koestler’s qualifications to sit on the board include his years of senior executive experience in the pharmaceutical industry, including his involvement with over 80 product approvals during his career, including 30 related to new molecular entities.
Elizabeth Stoner, M.D., has been a director since October 2007. Since September 2012, Dr. Stoner has been the Chief Development Officer at Vascular Pharmaceuticals, Inc., a biotechnology company. Between March 2010 and December 2014, Dr. Stoner was the Chief Development Officer of Rhythm Pharmaceuticals, and since December 2014, she has been a member of Rhythm’s Scientific Advisory Board. Since October 2007, Dr. Stoner has served as a Managing Director at MPM Capital, a healthcare venture capital firm. Prior to joining MPM Capital, Dr. Stoner had a distinguished 22‑year career at Merck Research Laboratories. At the time of her retirement from Merck, Dr. Stoner was Senior Vice President of Global Clinical Development Operations with responsibility for the company’s clinical development activities in more than 40 countries, including Merck’s Japanese subsidiary. Prior to her position at Merck, she was an Assistant Professor of Pediatrics at Cornell University Medical College. Dr. Stoner served on the board of Radius Health, Inc. from 2011 to 2015. Dr. Stoner received her B.S. in Chemistry from Ottawa University, KS, her M.S. in Chemistry from the State University of New York at Stony Brook, and her M.D. from Albert Einstein College of Medicine. Dr. Stoner’s qualifications to sit on the board include her more than 20 years of senior executive experience in the pharmaceutical industry, including her expertise in leading clinical development organizations.
Craig A. Wheeler has served as our President and a director since August 2006 and was appointed our Chief Executive Officer effective September 2006. Prior to joining Momenta, Mr. Wheeler served as President of Chiron Biopharmaceuticals, a division of Chiron Corporation, a biotechnology company, from August 2001 until June 2006. Mr. Wheeler served as a director of Avanir Pharmaceuticals, Inc. from September 2005 to January 2015, including serving on the Governance and Audit Committees, and serving as Chairman of the board beginning May 2007. Since February 2014, Mr. Wheeler has been a member of the Generic Pharmaceutical Association. Mr. Wheeler received B.S. and M.S. degrees in chemical engineering from Cornell University and an M.B.A. degree from the Wharton School of the University of Pennsylvania. Mr. Wheeler’s qualifications to sit on the board include his years of senior executive management experience in the biotechnology industry, including over seven years as our President and Chief Executive Officer and his experience serving on the board and committees at Avanir Pharmaceuticals.
Last Updated 1/3/2017